A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1a (Avonex)

Journal of Neuroscience Nursing

Volumn 40, Issue 6, 2008, Pages 350-355

  Freedman, S Mitchell ^a,b   Cox, Darcy ^c   Rosebrough, Teresa ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Raleigh Neurology Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; IMMUNOLOGICAL ADJUVANT;

ANXIETY; ARTICLE; ATTITUDE TO HEALTH; COMPARATIVE STUDY; DRUG SELF ADMINISTRATION; EQUIPMENT DESIGN; FEAR; FEMALE; HUMAN; INSTRUMENTATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; NEEDLE; NURSING; NURSING METHODOLOGY RESEARCH; PAIN; PAIN ASSESSMENT; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRE;

ADJUVANTS, IMMUNOLOGIC; ANXIETY; ATTITUDE TO HEALTH; EQUIPMENT DESIGN; FEAR; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; NEEDLES; NURSING METHODOLOGY RESEARCH; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRES; SELF ADMINISTRATION;

EID: 61549126622     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/01376517-200812000-00007     Document Type: Article

References (29)

1. American College of Physicians Task Force on Adult Immunization, Infectious Diseases Society of America. (1994). Guide for adult immunization (3rd ed.). Philadelphia: American College of Physicians.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed., pp. 405-411). Washington, DC: Author.
3. Berlex Laboratories. (2003). Betaseron [Package insert]. Montville, NJ: Author.
4. Biogen Idec, Inc. (2005). Avonex [Package insert]. Cambridge, MA: Author.
5. Centers for Disease Control and Prevention. (2002). General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). Morbidity and Mortality Weekly Report, 51 (RR-02), 1-36.
6. Cook, I. F., Williamson, M., & Pond, D. (2006). Definition of needle length required for intramuscular deltoid injection in elderly adults: An ultrasonographic study. Vaccine, 24, 937-940.
7. Durelli, L., Verdun, E., Barbero, P., Berqui, M., Versino, E., Ghezzi, A., et al. (2002). Every-other-day interferon beta-1b versus onceweekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet, 359, 1453-1460.
8. Frohman, E. M., Brannon, K., Alexander, S., Sims, D., Phillips, J. T., O'Leary, S., et al. (2004). Disease modifying agent related skin reactions in multiple sclerosis: Prevention, assessment, and management. Multiple Sclerosis, 10, 302-307.
9. Haas, J., & Firzlaff, M. (2005). Twenty-four month comparison of immunomodulatory treatments-A retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology, 12, 425-431.
10. Hornblow, A. R., & Kidson, M. A. (1976). The visual analogue scale for anxiety: A validation study. The Australian and New Zealand Journal of Psychiatry, 10, 339-341.
11. IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43, 655-661.
12. Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology, 39, 285-294.
13. Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 45, 1268-1276.
14. Milanese, C., La Mantia, L., Palumbo, R., Martinelli, V., Murialdo, A., Zaffaroni, M., et al. (2003). A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 1689-1692.
15. Miller, M. D., & Ferris, D. G. (1993). Measurement of subjective phenomena in primary care research: The visual analogue scale. Family Practice Research Journal, 13, 15-24.
16. Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125-132.
17. Mollema, E. D., Snoek, F. J., Heine, R. J., & van der Ploeg, H. M. (2001). Phobia of self-injecting and self-testing in insulin-treated diabetes patients: Opportunities for screening. Diabetes Medicine, 18, 671-674.
18. Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O'Connor, P., et al. (2002). Randomized, comparative study of interferon beta-1a treatment regimens in MS. The EVIDENCE Trial. Neurology, 59, 1496-1506.
19. Patti, F., Pappalardo, A., Florio, C., Politi, G., Fiorilla, T., Reggio, E., et al. (2006). Effects of interferon beta-1a and-1b over time: 6-year results of an observational head-to-head study. Acta Neurologica Scandinavica, 113, 241-247.
20. Poland, G. A., Borrud, A., Jacobson, R. M., McDermott, K., Wollan, P. C., Brakke, D., et al. (1997). Determination of deltoid fat pad thickness: Implications for needle length in adult immunization. Journal of the American Medical Association, 277, 1709-1711.
21. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. (1998). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352, 1498-1504.
22. Rio, J., Tintoré, M., Nos, C., Téllez, N., Galán, I., & Montalban, X. (2005). Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. Journal of Neurology, 252, 795-800.
23. Schwartz, S., Hassman, D., Shelmet, J., Sievers, R., Weinstein, R., Liang, J., et al. (2004). A multicenter, open-label, randomized, twoperiod crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clinical Therapeutics, 26, 1663-1678.
24. Serono, Inc. (2005). Rebif [Package insert]. Rockland, MA: Author.
25. Strauss, K., De Gols, H., Letondeur, C., Matyjaszczyk, M., & Frid, A. (2002). Conference report: The Second Injection Technique Event (SITE), May 2000, Barcelona, Spain. Practical Diabetes International, 19, 17-21.
26. Teva Neuroscience, Inc. (2004). Copaxone [Package insert]. Kansas City, MO: Author.
27. Treadaway, K. D., Brannon, K. D., Morrison, A., Remington, G. M., Olek, M., Racke, M. K., et al. (2006). Factors that influence adherence with disease modifying therapy in multiple sclerosis [Abstract]. Neurology, 66 (Suppl.), A30.
28. Trojano, M., Liguori, M., Paolicelli, D., Zimatore, G. B., De Robertis, F., Avolio, C., et al. (2003). Interferon beta in relapsing-remitting multiple sclerosis: An independent postmarketing study in southern Italy. Multiple Sclerosis, 9, 451-457.
29. Zambanini, A., & Feher, M. D. (1997). Needle phobia in type 1 diabetes mellitus. Diabetic Medicine, 14, 321-323.